![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Satellos expects to begin first-in-human clinical trials mid-year for SAT-3247, an oral small molecule drug candidate in development as a novel regenerative medicine approach to treating DMD...
Satellos Bioscience Inc. ouvre les marchés Canada NewsWire TORONTO, le 15 mai 2024 TORONTO, le 15 mai 2024 /CNW/ - Frank Gleeson, cofondateur et chef de la direction de Satellos Bioscience...
Satellos Bioscience Inc. Opens the Market Canada NewsWire TORONTO, May 15, 2024 TORONTO, May 15, 2024 /CNW/ - Frank Gleeson Co-Founder and Chief Executive Officer, Satellos Bioscience Inc. (TSX:...
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...
- Conducted preclinical toxicology studies and GMP manufacturing of SAT-3247 - On track to initiate Phase 1 first-in-human clinical trials mid-2024 - Cash balance of $33.2 million at March 31...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...
- Engaged CRO for first-in-human SAT-3247 Phase 1 clinical study - Initiated GLP toxicity studies and GMP manufacturing of SAT-3247 - Continues to be on track to initiate first-in-human clinical...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.01 | 1.96078431373 | 0.51 | 0.64 | 0.5 | 152575 | 0.54816639 | CS |
4 | 0.02 | 4 | 0.5 | 0.64 | 0.49 | 74565 | 0.54371316 | CS |
12 | 0 | 0 | 0.52 | 0.64 | 0.38 | 72728 | 0.51776323 | CS |
26 | -0.1 | -16.1290322581 | 0.62 | 0.8 | 0.38 | 66869 | 0.5485676 | CS |
52 | -0.1 | -16.1290322581 | 0.62 | 0.8 | 0.38 | 66869 | 0.5485676 | CS |
156 | -0.1 | -16.1290322581 | 0.62 | 0.8 | 0.38 | 66869 | 0.5485676 | CS |
260 | -0.1 | -16.1290322581 | 0.62 | 0.8 | 0.38 | 66869 | 0.5485676 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions